Abstract
Purpose
While SWI/SNF chromatin remodeling complex alterations occur in approximately 20% of cancer, the frequency and potential impact on clinical outcomes in meningiomas remains to be comprehensively elucidated.
Methods
A large series of 255 meningiomas from a single institution that was enriched for high grade and recurrent lesions was identified. We performed next-generation targeted sequencing of known meningioma driver genes, including NF2, AKT1, PIK3CA, PIK3R1, and SMO and SWI/SNF chromatin remodeling complex genes, including ARID1A, SMARCA4, and SMARCB1 in all samples. Clinical correlates focused on clinical presentation and patient outcomes are presented.
Results
The series included 63 grade I meningiomas and 192 high-grade meningiomas, including 173 WHO grade II and 19 WHO grade III. Samples from recurrent surgeries comprised 37.3% of the series. A total of 41.6% meningiomas were from the skull base. NF2, AKT1, PIK3CA, PIK3R1, and SMO were mutated in 40.8, 7.1, 3.5, 3.9, and 2.4% of samples, respectively. ARID1A, SMARCA4, and SMARCB1 mutations were observed in 17.3, 3.5, and 5.1% of samples, respectively. A total of 68.2% of ARID1A-mutant meningiomas harbored a p.Gln1327del in-frame deletion. ARID1A mutations were seen in 19.1% of Grade I, 16.8% of Grade II, and 15.8% of Grade III meningiomas (P = 0.9, Fisher’s exact). Median overall survival was 16.3 years (95% CI 10.9, 16.8). With multivariable analysis, the presence of an ARID1A mutation was significantly associated with a 7.421-fold increased hazard of death (P = 0.04).
Conclusion
ARID1A mutations occur with similar frequency between low and high-grade meningiomas, but ARID1A mutations are independently prognostic of worse prognosis beyond clinical and histopathologic features.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data presented and included herein.
References
Abedalthagafi MS, Bi WL, Merrill PH et al (2015) ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet 208:345–350. https://doi.org/10.1016/j.cancergen.2015.03.005
Abedalthagafi M, Bi WL, Aizer AA et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. https://doi.org/10.1093/neuonc/nov316
Agnihotri S, Jalali S, Wilson MR et al (2016) The genomic landscape of schwannoma. Nat Genet 48:1339–1348. https://doi.org/10.1038/ng.3688
Bacci C, Sestini R, Provenzano A et al (2010) Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics 11:73–80. https://doi.org/10.1007/s10048-009-0204-2
Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A et al (2013) ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS ONE 8:e62483. https://doi.org/10.1371/journal.pone.0062483
Biczok A, Kraus T, Suchorska B et al (2018) TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neurooncol 139:671–678. https://doi.org/10.1007/s11060-018-2912-7
Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289. https://doi.org/10.1038/ng.2526
Bui C-B, Le HK, Vu DM et al (2019) ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT. Mol Carcinog 58:1998–2007. https://doi.org/10.1002/mc.23091
Bujko M, Machnicki MM, Grecka E et al (2017) Mutational analysis of recurrent meningioma progressing from atypical to rhabdoid subtype. World Neurosurg 97:754.e1-754.e6. https://doi.org/10.1016/j.wneu.2016.10.047
Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095
Cho H, Kim JS-Y, Chung H et al (2013) Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol 44:1365–1374. https://doi.org/10.1016/j.humpath.2012.11.007
Cho HD, Lee JE, Jung HY et al (2015) Loss of tumor suppressor ARID1A protein expression correlates with poor prognosis in patients with primary breast cancer. J Breast Cancer 18:339. https://doi.org/10.4048/jbc.2015.18.4.339
Christiaans I, Kenter SB, Brink HC et al (2011) Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet 48:93–97. https://doi.org/10.1136/jmg.2010.082420
Clark VE, Erson-Omay EZ, Serin A et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009
Clark VE, Harmancı AS, Bai H et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253–1259. https://doi.org/10.1038/ng.3651
Collord G, Tarpey P, Kurbatova N et al (2018) An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Sci Rep 8:13537. https://doi.org/10.1038/s41598-018-31659-0
Cong Y-S, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407–425. https://doi.org/10.1128/MMBR.66.3.407-425.2002
Evans LT, Van Hoff J, Hickey WF et al (2015) SMARCE1 mutations in pediatric clear cell meningioma: case report. J Neurosurg Pediatr 16:296–300. https://doi.org/10.3171/2015.3.PEDS14417
Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. https://doi.org/10.1126/scisignal.2004088
Gill CM, Loewenstern J, Rutland JW et al (2020a) Recurrent IDH mutations in high-grade meningioma. Neuro Oncol. https://doi.org/10.1093/neuonc/noaa065
Gill CM, Loewenstern J, Rutland JW et al (2020b) In reply: retention of ATRX and DAXX expression in meningiomas. Neurosurgery 86:E244–E246. https://doi.org/10.1093/neuros/nyz504
Gill CM, Loewenstern J, Rutland JW et al (2020c) STK11 mutation status is associated with decreased survival in meningiomas. Neurol Sci. https://doi.org/10.1007/s10072-020-04372-y
Goutagny S, Nault JC, Mallet M et al (2014) High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression: TERT promoter mutations in meningioma progression. Brain Pathol 24:184–189. https://doi.org/10.1111/bpa.12110
Harmancı AS, Youngblood MW, Clark VE et al (2017) Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun 8:14433. https://doi.org/10.1038/ncomms14433
He F, Li J, Xu J et al (2015) Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma. J Exp Clin Cancer Res. https://doi.org/10.1186/s13046-015-0164-3
Isharwal S, Audenet F, Drill E et al (2019) Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma. Eur Urol Focus 5:201–204. https://doi.org/10.1016/j.euf.2017.07.004
Itamochi H, Oumi N, Oishi T et al (2015) Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. Int J Clin Oncol 20:967–973. https://doi.org/10.1007/s10147-015-0811-x
Jungwirth G, Warta R, Beynon C et al (2019) Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol Commun 7:140. https://doi.org/10.1186/s40478-019-0793-4
Kadoch C, Hargreaves DC, Hodges C et al (2013) Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45:592–601. https://doi.org/10.1038/ng.2628
Katagiri A, Nakayama K, Rahman MT et al (2012) Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25:282–288. https://doi.org/10.1038/modpathol.2011.161
Lichner Z, Scorilas A, White NMA et al (2013) The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol 182:1163–1170. https://doi.org/10.1016/j.ajpath.2013.01.007
Loewenstern J, Rutland J, Gill C et al (2019) Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas. Oncotarget 10:3506–3517. https://doi.org/10.18632/oncotarget.26941
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Luchini C, Veronese N, Solmi M et al (2015) Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget 6:39088–39097. https://doi.org/10.18632/oncotarget.5142
Melean G, Velasco A, Hernández-Imaz E et al (2012) RNA-based analysis of two SMARCB1 mutations associated with familial schwannomatosis with meningiomas. Neurogenetics 13:267–274. https://doi.org/10.1007/s10048-012-0335-8
Nagl NG, Wang X, Patsialou A et al (2007) Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 26:752–763. https://doi.org/10.1038/sj.emboj.7601541
Onder S, Fayda M, Karanlık H et al (2017) Loss of ARID1A expression is associated with poor prognosis in invasive micropapillary carcinomas of the breast: a clinicopathologic and immunohistochemical study with long-term survival analysis. Breast J 23:638–646. https://doi.org/10.1111/tbj.12823
Pain M, Wang H, Lee E et al (2018) Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. Oncotarget 9:2603–2621. https://doi.org/10.18632/oncotarget.23517
Park JH, Lee C, Suh JH et al (2015) Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. Hum Pathol 46:454–460. https://doi.org/10.1016/j.humpath.2014.12.002
Pepe F, Pisapia P, de BassoCaro MLD et al (2019) Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. Histol Histopathol. https://doi.org/10.14670/HH-18-195
Raffalli-Ebezant H, Rutherford SA, Stivaros S et al (2015) Pediatric intracranial clear cell meningioma associated with a germline mutation of SMARCE1: a novel case. Childs Nerv Syst 31:441–447. https://doi.org/10.1007/s00381-014-2558-5
Rahmanto YS, Jung J-G, Wu R-C et al (2016) Inactivating ARID1A tumor suppressor enhances TERT transcription and maintains telomere length in cancer cells. J Biol Chem 291:9690–9699. https://doi.org/10.1074/jbc.M115.707612
Reuss DE, Piro RM, Jones DTW et al (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125:351–358. https://doi.org/10.1007/s00401-013-1093-x
Roy S, LaFramboise WA, Liu T-C et al (2018) Loss of chromatin-remodeling proteins and/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times. Gastroenterology 154:2060-2063.e8. https://doi.org/10.1053/j.gastro.2018.02.026
Schmitz U, Mueller W, Weber M et al (2001) INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 84:199–201. https://doi.org/10.1054/bjoc.2000.1583
Shen J, Peng Y, Wei L et al (2015) ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov 5:752–767. https://doi.org/10.1158/2159-8290.CD-14-0849
Simbolo M, Vicentini C, Ruzzenente A et al (2018) Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. https://doi.org/10.1038/s41598-018-25669-1
Smith MJ, O’Sullivan J, Bhaskar SS et al (2013) Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 45:295–298. https://doi.org/10.1038/ng.2552
Smith MJ, Wallace AJ, Bennett C et al (2014) Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 234:436–440. https://doi.org/10.1002/path.4427
Strickland MR, Gill CM, Nayyar N et al (2017) Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg 127:438–444. https://doi.org/10.3171/2016.8.JNS161076
Tang M, Wei H, Han L et al (2017) Whole-genome sequencing identifies new genetic alterations in meningiomas. Oncotarget 8:17070–17080. https://doi.org/10.18632/oncotarget.15043
van den Munckhof P, Christiaans I, Kenter SB et al (2012) Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13:1–7. https://doi.org/10.1007/s10048-011-0300-y
Weissman B, Knudsen KE (2009) Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res 69:8223–8230. https://doi.org/10.1158/0008-5472.CAN-09-2166
Williams S, Castro B, Lazaro T et al (2017) Clinically-actionable mutations in posterior skull base meningiomas. J Neurol Surg B: Skull Base 78:S1–S156. https://doi.org/10.1055/s-0037-1600551
Williams EA, Wakimoto H, Shankar GM et al (2020) Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. https://doi.org/10.1007/s00401-020-02161-7
Wu JN, Roberts CWM (2013) ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov 3:35–43. https://doi.org/10.1158/2159-8290.CD-12-0361
Wu R-C, Wang T-L, Shih I-M (2014) The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 15:655–664. https://doi.org/10.4161/cbt.28411
Xu N, Wang L, Sun P et al (2019) Low ARID1A expression correlates with poor prognosis and promotes cell proliferation and metastasis in osteosarcoma. Pathol Oncol Res 25:875–881. https://doi.org/10.1007/s12253-017-0338-8
Yang L, Wei S, Zhao R et al (2016) Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies. Sci Rep. https://doi.org/10.1038/srep28919
Yang L, Yang G, Ding Y et al (2018) Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. Oncol Rep. https://doi.org/10.3892/or.2018.6445
Yokoyama Y, Matsushita Y, Shigeto T et al (2014) Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol 25:58. https://doi.org/10.3802/jgo.2014.25.1.58
Youngblood MW, Duran D, Montejo JD et al (2019) Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg. https://doi.org/10.3171/2019.8.JNS191266
Zhang X, Zhang Y, Yang Y et al (2012) Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 36:288–293. https://doi.org/10.1016/j.canep.2011.07.006
Zhao J, Liu C, Zhao Z (2014) ARID1A: a potential prognostic factor for breast cancer. Tumor Biol 35:4813–4819. https://doi.org/10.1007/s13277-014-1632-7
Zhao X-S, Zhou J, Dong L et al (2019) Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation. Chin Med J 132:3012–3014. https://doi.org/10.1097/CM9.0000000000000550
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethics approval
This study was reviewed and approved by the human subjects institutional review board and complied with HIPAA (Health Insurance Portability and Accountability Act of 1996) guidelines.
Consent to participate
Informed consent was waived.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gill, C.M., Loewenstern, J., Rutland, J.W. et al. SWI/SNF chromatin remodeling complex alterations in meningioma. J Cancer Res Clin Oncol 147, 3431–3440 (2021). https://doi.org/10.1007/s00432-021-03586-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03586-7